CMS announces two drug manufacturers to participate in CGT Access Model 

Dec 04, 2024 - 04:01 PM
cms-lab-reporting

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex Pharmaceuticals (manufacturer of Casgevy) will participate in its Cell and Gene Therapy Access Model. The voluntary model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative treatment and reduces health care expenditures. The CGT Access Model launches in January, and states can choose to begin participation anytime between then and January 2026. The state application portal will also go live this month and remain open through Feb. 28, 2025. In addition, states may apply for optional model funding by Feb. 28, 2025 through the notice of funding opportunity. 

Related News Articles

Headline
OIG says MA, Medicaid managed care plans have limited, inaccurate behavioral health provider networks 
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…
Headline
Study finds Medicaid beneficiaries most likely to lose coverage due to work requirements have worse health  
A JAMA study published yesterday analyzed the health characteristics of individuals projected to lose Medicaid coverage due to work requirements included in…
Headline
CMS releases updated guidance to states on federal financing for emergency Medicaid services 
The Centers for Medicare & Medicaid Services Sept. 30 released guidance to states clarifying its interpretation of a provision that…
Headline
Hospital-at-home bill considered during House Ways and Means Committee markup
The AHA submitted a statement Sept. 17 for a House Ways and Means Committee markup session on a series of health care and other bills. Specifically, the AHA…
Headline
Bipartisan letter urges House leadership to halt Medicaid DSH cuts
A bipartisan House letter by Reps. Dan Crenshaw, R-Texas, Yvette D. Clarke, D-N.Y., Gus M. Bilirakis, R-Fla., and Diana DeGette, D-Colo., urged House…
Headline
AHA highlights key health care priorities for House, Senate leaders to address by end of year 
The AHA detailed its key health care priorities for the remainder of the year in comments to House and Senate majority and minority leaders Sept. 15. The AHA…